专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07396842B2 Five-membered cyclic compounds 失效
标题翻译：五元环化合物
公开(公告)号：US07396842B2
公开(公告)日：2008-07-08
申请号：US11111845
申请日：2005-04-22
申请人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
发明人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
IPC分类号： A61K31/44 , C07D417/00
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D277/42 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14
摘要： A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.
摘要翻译：下式的5元环状化合物：其中X是氧或硫，R 1是氢，取代或未取代的烷基等，R 2是氢，被取代的或未取代的烷基，取代或未取代的芳基等，Y 1是直接键，取代或未取代的亚烷基，-CO（CH 2）n，（E）构型或（Z）构型，R 3是取代或未取代的芳基等。Y 2 - 是取代或未取代的亚烷基等，R 4是氢，取代或未取代的烷酰基，取代或未取代的烷基等，R 5是氢等，或其盐，这些化合物能够抑制白细胞如嗜酸性粒细胞和淋巴细胞的浸润，由此可用于治疗各种炎症。

2. 发明申请

US20050222226A1 Five-membered cyclic compounds 失效
标题翻译：五元环化合物
公开(公告)号：US20050222226A1
公开(公告)日：2005-10-06
申请号：US11111845
申请日：2005-04-22
申请人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
发明人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
IPC分类号： A61P29/00 , A61P37/06 , A61P37/08 , C07D277/42 , C07D277/56 , C07D417/04 , C07D417/12 , C07D417/14 , C07D521/00 , A61K31/426 , C07D277/38
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D277/42 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14
摘要： A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.
摘要翻译：下式的5元环状化合物：其中X是氧或硫，R 1是氢，取代或未取代的烷基等，R 2是氢，被取代的或未取代的烷基，取代或未取代的芳基等，Y 1是直接键，取代或未取代的亚烷基，-CO（CH 2）n，（E）构型或（Z）构型，R 3是取代或未取代的芳基等。Y 2 - 是取代或未取代的亚烷基等，R 4是氢，取代或未取代的烷酰基，取代或未取代的烷基等，R 5是氢等，或其盐，这些化合物能够抑制白细胞如嗜酸性粒细胞和淋巴细胞的浸润，由此可用于治疗各种炎症。

3. 发明授权

US06919361B2 Five-membered-ring compound 失效
标题翻译：五元环化合物
公开(公告)号：US06919361B2
公开(公告)日：2005-07-19
申请号：US10312692
申请日：2001-06-28
申请人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
发明人： Norio Fujiwara , Hitoshi Fujita , Fujio Antoku , Toshinari Sugasawa , Hajime Kawakami
IPC分类号： A61P29/00 , A61P37/06 , A61P37/08 , C07D277/42 , C07D277/56 , C07D417/04 , C07D417/12 , C07D417/14 , C07D521/00 , A61K31/425 , C07P277/08
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D277/42 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14
摘要： A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.
摘要翻译：下式的5元环状化合物：其中X是氧或硫，R 1是氢，取代或未取代的烷基等，R 2是氢，被取代的或未取代的烷基，取代或未取代的芳基等，Y 1是直接键，取代或未取代的亚烷基，-CO（CH 2）n，（E）构型或（Z）构型，R 3是取代或未取代的芳基等。Y 2 - 是取代或未取代的亚烷基等，R 4是氢，取代或未取代的烷酰基，取代或未取代的烷基等，R 5是氢等，或其盐，这些化合物能够抑制白细胞如嗜酸性粒细胞和淋巴细胞的浸润，由此可用于治疗各种炎症。

4. 发明授权

US06458798B1 Bicyclic pyrimidine compounds and therapeutic use thereof 失效
标题翻译：双环嘧啶化合物及其治疗用途
公开(公告)号：US06458798B1
公开(公告)日：2002-10-01
申请号：US09763728
申请日：2001-02-27
申请人： Hitoshi Fujita , Fujio Antoku , Norio Fujiwara , Kiyotaka Iwai , Hiroshi Tanaka , Hajime Kawakami
发明人： Hitoshi Fujita , Fujio Antoku , Norio Fujiwara , Kiyotaka Iwai , Hiroshi Tanaka , Hajime Kawakami
IPC分类号： C07D23995
CPC分类号： C07D405/04 , C07D405/12 , C07D405/14
摘要： A pyrimidine derivative of the formula (1) or a salt thereof; has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as systemic lupus erythemathosus, etc., and acquired immunodeficiecy syndrome (AIDS) and so on.
摘要翻译：式（1）的嘧啶衍生物或其盐具有产生Th2型细胞因子如IL-4，IL-5等的抑制活性，可用作过敏性疾病，自身免疫性疾病的治疗剂如系统性红斑狼疮等，以及获得性免疫缺陷综合征（AIDS）等。

5. 发明授权

US06951866B2 Bicyclic pyrimidine compounds and therapeutic use thereof 失效
标题翻译：双环嘧啶化合物及其治疗用途
公开(公告)号：US06951866B2
公开(公告)日：2005-10-04
申请号：US10222922
申请日：2002-08-19
申请人： Hitoshi Fujita , Fujio Antoku , Norio Fujiwara , Kiyotaka Iwai , Hiroshi Tanaka , Hajime Kawakami
发明人： Hitoshi Fujita , Fujio Antoku , Norio Fujiwara , Kiyotaka Iwai , Hiroshi Tanaka , Hajime Kawakami
IPC分类号： C07D405/04 , C07D405/12 , C07D405/14 , C07D491/044 , C07D491/052 , C07D239/49 , A61K31/505 , C07D239/48
CPC分类号： C07D405/04 , C07D405/12 , C07D405/14
摘要： 1. A pyrimidine derivative of the formula (1) or a salt thereof; has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as systemic lupus erythemathosus, etc., and acquired immunodeficiecy syndrome (AIDS) and so on.
摘要翻译： 1.式（1）的嘧啶衍生物或其盐; 具有产生Th2型细胞因子如IL-4，IL-5等的抑制活性，可用作过敏性疾病，系统性红斑狼疮等自身免疫性疾病等治疗剂，以及获得性免疫缺陷综合征艾滋病）等。

6. 发明授权

US5948786A Piperidinylpyrimidine derivatives 失效
标题翻译：哌啶基嘧啶衍生物
公开(公告)号：US5948786A
公开(公告)日：1999-09-07
申请号：US69085
申请日：1998-04-29
申请人： Norio Fujiwara , Yutaka Ueda , Shinobu Murata , Fumiyo Hirota , Hajime Kawakami , Hitoshi Fujita
发明人： Norio Fujiwara , Yutaka Ueda , Shinobu Murata , Fumiyo Hirota , Hajime Kawakami , Hitoshi Fujita
IPC分类号： A61K31/506 , A61K31/517 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/505 , C07D239/02 , C07D401/00
CPC分类号： C07D401/04 , A61K31/506 , A61K31/517 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： A compound of formula (1) ##STR1## wherein X.sup.1 is amino or hydroxyl, X.sup.2 is carbonyl and the like R.sup.1 is an alkyl, an aryl and the like, R.sup.2 is hydrogen and the like, and R.sup.3 is an alkyl and the like, or a pharmaceutical acceptable salt thereof is effective for inibiting the production and/or secretion of tumor necrosis factor in a patient in need of such inhibition.
摘要翻译：式（1）的化合物，其中X 1为氨基或羟基，X 2为羰基等，R 1为烷基，芳基等，R 2为氢等，R 3为烷基等，或药物其可接受的盐对于在需要这种抑制的患者中抑制肿瘤坏死因子的产生和/或分泌是有效的。

7. 发明授权

US08012971B2 Therapeutic agent for chronic obstructive pulmonary disease 失效
标题翻译：慢性阻塞性肺疾病治疗剂
公开(公告)号：US08012971B2
公开(公告)日：2011-09-06
申请号：US11919135
申请日：2006-04-28
申请人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
发明人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
IPC分类号： A61K31/426 , A61K31/5377 , C07D417/10 , C07D277/38
CPC分类号： A61K31/56 , A61K9/10 , A61K31/5377 , C07D277/42
摘要： Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.
摘要翻译：本发明公开了一种预防和/或治疗慢性阻塞性肺疾病的方法，该方法是通过给予由下式表示的5元环状化合物：或化合物的药学上可接受的盐或其化合物或盐的前体药物：其中X 表示氧或硫原子; R1表示氢原子，取代或未取代的烷基等; R 2表示氢原子，取代或未取代的烷基等; Y1表示单键，取代或未取代的亚烷基等; 波浪线表示（E）或（Z）配位; R3表示氢原子，取代或未取代的芳基等; Y2表示取代或未取代的亚烷基或亚烯基; R4表示氢原子，取代或未取代的烷酰基等; 并且R 5表示氢原子或取代或未取代的烷基。

8. 发明申请

US20090131439A1 Therapeutic agent for chronic obstructive pulmonary disease 失效
标题翻译：慢性阻塞性肺疾病治疗剂
公开(公告)号：US20090131439A1
公开(公告)日：2009-05-21
申请号：US11919135
申请日：2006-04-28
申请人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
发明人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
IPC分类号： A61K31/426 , A61K31/5377 , A61P11/00 , C07D417/10 , C07D277/38
CPC分类号： A61K31/56 , A61K9/10 , A61K31/5377 , C07D277/42
摘要： Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.
摘要翻译：本发明公开了一种预防和/或治疗慢性阻塞性肺疾病的方法，该方法是通过给予由下式表示的5元环状化合物：或化合物的药学上可接受的盐或其化合物或盐的前体药物：其中X 表示氧或硫原子; R1表示氢原子，取代或未取代的烷基等; R 2表示氢原子，取代或未取代的烷基等; Y1表示单键，取代或未取代的亚烷基等; 波浪线表示（E）或（Z）配位; R3表示氢原子，取代或未取代的芳基等; Y2表示取代或未取代的亚烷基或亚烯基; R4表示氢原子，取代或未取代的烷酰基等; 并且R 5表示氢原子或取代或未取代的烷基。

9. 发明申请

US20110263550A1 THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
标题翻译：慢性阻塞性肺疾病治疗药物
公开(公告)号：US20110263550A1
公开(公告)日：2011-10-27
申请号：US13084503
申请日：2011-04-11
申请人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
发明人： Toshinari Sugasawa , Takashi Nakajima , Hitoshi Fujita , Toshio Kanai
IPC分类号： A61K31/56 , A61P11/00 , A61K31/5377
CPC分类号： A61K31/56 , A61K9/10 , A61K31/5377 , C07D277/42
摘要： Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.
摘要翻译：本发明公开了一种预防和/或治疗慢性阻塞性肺疾病的方法，该方法是通过给予由下式表示的5元环状化合物：或化合物的药学上可接受的盐或其化合物或盐的前体药物：其中X 表示氧或硫原子; R1表示氢原子，取代或未取代的烷基等; R 2表示氢原子，取代或未取代的烷基等; Y1表示单键，取代或未取代的亚烷基等; 波浪线表示（E）或（Z）配位; R3表示氢原子，取代或未取代的芳基等; Y2表示取代或未取代的亚烷基或亚烯基; R4表示氢原子，取代或未取代的烷酰基等; 并且R 5表示氢原子或取代或未取代的烷基。

10. 发明授权

US06907095B1 Clock ride-over method and circuit 失效
标题翻译：时钟转换方法和电路
公开(公告)号：US06907095B1
公开(公告)日：2005-06-14
申请号：US09709203
申请日：2000-11-09
申请人： Fumio Nakano , Hitoshi Fujita
发明人： Fumio Nakano , Hitoshi Fujita
IPC分类号： H03K21/38 , H04L7/00 , H04L7/04
CPC分类号： H04L7/0012
摘要： A clock ride-over circuit in which clock ride-over may be achieved even if jitter is contained in clocks prior to and subsequent to ride-over and no control input signal for write and readout is applied from outside. A clock prior to rideover CLK—1 is detected by a clock subsequent to ride-over CLK—2 which is of a higher speed than the clock prior to ride-over. A timing signal TIM of a constant period, generated by a counter adapted for self-running with the clock prior to ride-over, is compared to the phase comparison signal COMP which is the result of the clock detection. Stable clock ride-over is possible by the phase comparison signal COMP having a pulse width larger than the jitter period of the clock subsequent to ride-over.
摘要翻译：即使在骑乘之前和之后的时钟中包含抖动也可以实现时钟转换的时钟转换电路，并且不从外部施加用于写入和读出的控制输入信号。 Rideover之前的一个时钟CLK乘以一个比乘法之前的时钟更快的乘法器CLK-2之后的时钟来检测。由适应于在乘坐之前的时钟自行运行的计数器产生的恒定周期的定时信号TIM与作为时钟检测结果的相位比较信号COMP进行比较。可以通过相位比较信号COMP具有比乘坐后的时钟的抖动周期大的脉冲宽度的稳定的时钟跳变。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式